Industry News

NIH Awards USD 1.6 Million Grant to Subtle Medical

By Medimaging International staff writers
03 Oct 2019

Image: Subtle Medical’s AI product SubtleGAD reduces the gadolinium needed during MRI exams without sacrificing diagnostic quality (Photo courtesy of iStock).The National Institutes of Health {(NIH) Bethesda, MA, USA} has awarded healthcare technology company Subtle Medical (Menlo Park, CA, USA) a Fast-Track Small Business Innovation Research (SBIR) grant of USD 1.6 million. The 2.5-year fast track to Phase 2 award will fund an artificial intelligence (AI) product, SubtleGAD, in development by Subtle Medical aimed at reducing gadolinium dosage needed during MRI exams using deep learning (DL). The work will lead to safer contrast-enhanced MRI.

Over 40 million MRI scans are performed annually. Gadolinium-based contrast agents (GBCAs) are used in approximately one-third of all MRI scans. The usage of GBCAs has been linked to the development of nephrogenic systemic fibrosis (NSF). NSF can be painful, cause severe disability, and even death. The recent identification of gadolinium deposition within the brain and body has raised additional safety concerns about the usage of GBCAs. The FDA recently issued warnings about gadolinium retention following contrast-enhanced MRI and required GBCA manufacturers to conduct human and animal studies to further assess the safety of these contrast agents.

Subtle Medical, a healthcare technology company out of Stanford University, has developed a suite of deep learning solutions that enable centers to increase medical imaging speed, improve patient experience and reduce cost. Subtle's first product, SubtlePET, is the first FDA-cleared and CE-marked AI solution for medical imaging enhancement, enabling centers to enhance images from up to 4x faster PET scans. Subtle's second product, SubtleMR, currently under FDA review, was developed with the aim of faster MRI exams. SubtleGAD is the third product under development in Subtle Medical's growing portfolio of new AI technologies. The low-dose contrast-enhanced MRI method will benefit not only millions of patients with advanced chronic kidney disease (CKD) who cannot currently undergo contrast-enhanced MRI, but many more patients with normal kidney function, who are at the risk of gadolinium retention after a contrast-enhanced MRI.

"With SubtleGAD technology, hospitals and imaging centers will be able to deliver safer MRI exams without sacrificing the clinical quality of the images," said Enhao Gong, PhD, Co-founder & CEO of Subtle Medical. "We are grateful to receive NIH's support to further the development of our AI product and bring it into clinical use."

Related Links:
National Institutes of Health
Subtle Medical

E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

23 Jun 2020
Omnia Health Live Unites Global Healthcare Community Through New Virtual Experience
Omnia Health Live, a virtual healthcare event, has brought the global healthcare community together on a scale never seen before through a new experience delivered entirely online.
Read More
12 Jun 2020
Global Magnetic Resonance Imaging (MRI) Market to be driven by Advancements in Medical Diagnostics
The global magnetic resonance imaging (MRI) market was valued at USD 5.90 billion in 2017 and is projected to register a CAGR of 5.2% from 2018 to 2026, driven by increased demand for MRI equipment across the world due to a substantial rise in incidence of disorders related to spine, neurology, orthopedic, cardiovascular, head and neck, and abdominal and prostate.
Read More
30 May 2020
MEDICAL FAIR ASIA 2020 Set to Take Place in Singapore from 9-11 December 2020
MEDICAL FAIR ASIA 2020 is set to take place in Singapore from 9-11 December 2020 at Marina Bay Sands, with the exhibition featuring the latest medical technology and innovations, and healthcare equipment and supplies.
Read More
20 Apr 2020
Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries
Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose, ketone, hemoglobin, and hematocrit in six to 40 seconds with laboratory-quality results.
Read More
20 Apr 2020
Nova's Stat Profile Prime Plus Blood Gas Analyzer Receives FDA Clearance for POC Use
Nova Biomedical (Waltham, MA, USA) has secured clearance from the US Food and Drug Administration (FDA) for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use.
Read More
17 Apr 2020
ECR 2020 to Go Ahead as Online Congress on July 15-19, 2020
In view of the ongoing spread of COVID-19 across the world and its growing global impact, the board of directors of the European Society of Radiology (Vienna) has decided not to hold an onsite European Congress of Radiology (ECR) in 2020. Instead, ECR 2020 will go ahead as an online congress to ensure a safe experience for its members, partners, staff and the general public.
Read More
08 Apr 2020
Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Read More
01 Apr 2020
SymphonyAI Acquires TeraRecon
SymphonyAI Group (Los Altos, CA, USA), an operating group of leading business-to-business artificial intelligence (AI) companies, has acquired TeraRecon (Durham, NC, USA), an advanced visualization and AI solution provider for medical imaging.
Read More
23 Mar 2020
Artificial Intelligence-Based Methods to Cut MRI Read Times Receives USD 250K Grant
 Research to detect and predict blocked arteries and cardiovascular risk using knee MRI images conducted by Chun Yuan, Ph.D., Professor of Radiology and Bioengineering and Vice Chair for Global Affairs at the University of Washington (Seattle, WA, USA) has been recognized and awarded a grant by the American Heart Association’s (AHA) Institute for Precision Cardiovascular Medicine (Dallas, TX, USA).
Read More
Copyright © 2000-2020 All rights reserved. | Terms And Conditions